Beth Zha
Pulmonary Disease · San Francisco, CANPI 1396087342
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,168 of the $20,544 with a category attached, or 88.4%. Insmed, Inc. accounts for 68.5% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $9,966, more than ten times the $136 reported in 2019. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $760.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$14K
- Genentech, Inc.$3K
- Boehringer Ingelheim$3K
Across 132 payments — averaging $3576.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$470K
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Consulting fees$18,16888%
- Travel & lodging$1,6788%
- Food & beverage$6983%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 21 | $14,077 |
| Genentech, Inc. | 2 | $3,300 |
| Boehringer Ingelheim | 4 | $3,167 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,544 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 18 | $478,624 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 22 | $321,387 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 132 | $73,893 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 88 | $59,795 |
| Spiriva RespimatTiotropium Bromide | 53 | $40,534 |
| ColistimethateColistin (Colistimethate Na) | 37 | $14,874 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $14,315 |
| Spiriva HandihalerTiotropium Bromide | 14 | $12,452 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $10,206 |
| DuleraMometasone/Formoterol | 13 | $6,751 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $4,662 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 146 | $3,817 |
| Ceftazidime | 36 | $3,646 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 49 | $3,411 |
| Rifampin | 37 | $2,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $14,077 | $321,38722 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $3,167 | $110,535162 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in San Francisco
- Nicholas KolaitisSan Francisco$122K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.